Biosimilar Contract Manufacturing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2026

Description

The biosimilar contract manufacturing market is witnessing strong growth as pharmaceutical and biotechnology companies increasingly outsource complex biologics production to specialized manufacturing partners. The market is valued at USD 8.6 billion in 2025 and is projected to reach USD 21.3 billion by 2032, growing at a CAGR of 13.9% during the study period from 2019 to 2032. Rising demand for cost-effective biologic therapies, patent expirations of reference biologics, and growing acceptance of biosimilars are driving sustained market expansion.

Biosimilar developers are relying on contract manufacturing organizations to manage highly specialized processes such as cell line development, upstream and downstream processing, formulation, and regulatory compliance. Outsourcing enables faster scale-up, reduced capital investment, and improved time-to-market while maintaining high quality and consistency standards. Increasing focus on expanding biosimilar pipelines across oncology, autoimmune diseases, and chronic conditions is further strengthening demand for contract manufacturing services.

North America represents the largest regional market, supported by a strong biopharmaceutical ecosystem, advanced manufacturing infrastructure, and high biosimilar adoption, while the Asia-Pacific region is emerging as the fastest-growing market due to expanding biomanufacturing capacity, cost competitiveness, and rising participation of global contract manufacturers. As biosimilars gain wider regulatory and market acceptance, the biosimilar contract manufacturing market is expected to maintain robust growth throughout the forecast period.

Key Insights

The biosimilar contract manufacturing market is valued at USD 8.6 billion in 2025 and is expected to reach USD 21.3 billion by 2032, reflecting strong long-term growth driven by expanding biosimilar development pipelines.

The market is projected to grow at a CAGR of 13.9% during 2019-2032, supported by increasing outsourcing of biologics manufacturing and rising biosimilar approvals.

Growing demand for affordable biologic therapies is strengthening reliance on contract manufacturing organizations for biosimilar production.

North America accounts for the largest share of the global market, driven by advanced biopharmaceutical infrastructure and strong regulatory support for biosimilars.

The Asia-Pacific region is the fastest-growing market, supported by rapid expansion of biomanufacturing facilities and cost-efficient production capabilities.

Increasing complexity of biosimilar manufacturing is encouraging pharmaceutical companies to partner with specialized contract manufacturers.

Rising investment in bioprocess optimization and scalable manufacturing technologies is improving production efficiency and consistency.

Contract manufacturers are playing a critical role in supporting regulatory compliance and quality assurance across global markets.

Expansion of biosimilar pipelines in oncology and autoimmune disease treatment is increasing long-term manufacturing demand.

Continuous investment in biomanufacturing capacity, technology upgrades, and skilled workforce development is expected to sustain long-term growth in the biosimilar contract manufacturing market.

Product Code: 13813

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market Size Breakdown, by Product Type
- 1.4.2. Market Size Breakdown, by Source
- 1.4.3. Market Size Breakdown, by Service Type
- 1.4.4. Market Size Breakdown, by Therapeutic Area
- 1.4.5. Market Size Breakdown, by Region
- 1.4.6. Market Size Breakdown, by Country
1.5. Market Data Reporting Unit
- 1.5.1. Revenue
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence Database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Industry Background
5.2. Market Dynamics
- 5.2.1. Trends
- 5.2.2. Drivers
- 5.2.3. Restraints/Challenges
- 5.2.4. Emerging Economies and Key Opportunities
- 5.2.5. Impact Analysis of Drivers/Restraints
5.3. Sociopolitical Impact
5.4. Porter's Five Forces Analysis
- 5.4.1. Bargaining Power of Buyers
- 5.4.2. Bargaining Power of Suppliers
- 5.4.3. Threat of New Entrants
- 5.4.4. Intensity of Rivalry
- 5.4.5. Threat of Substitutes
5.5. Lifecycle Analysis
5.6. Innovation and Technology Trends
5.7. Economic and Regulatory Impact
5.8. Market Entry Strategies

Chapter 6. Competitive Landscape

6.1. List of Market Players and their Offerings
6.2. Market Share of Key Players (2025)
- 6.2.1. Global
- 6.2.2. North America
- 6.2.3. Europe
- 6.2.4. Asia-Pacific
- 6.2.5. Latin America
- 6.2.6. Middle East and Africa
6.3. Competitive Benchmarking of Key Players
6.4. Product Benchmarking of Key Players
6.5. Recent Strategic Developments by Key Players
6.6. Company Leadership Matrix

Chapter 7. Global Market

7.1. Overview
7.2. Market Revenue, by Product Type (2019-2032)
7.3. Market Revenue, by Source (2019-2032)
7.4. Market Revenue, by Service Type (2019-2032)
7.5. Market Revenue, by Therapeutic Area (2019-2032)
7.6. Market Revenue, by Region (2019-2032)

Chapter 8. North America Market

8.1. Overview
8.2. Market Revenue, by Product Type (2019-2032)
8.3. Market Revenue, by Source (2019-2032)
8.4. Market Revenue, by Service Type (2019-2032)
8.5. Market Revenue, by Therapeutic Area (2019-2032)
8.6. Market Revenue, by Country (2019-2032)

Chapter 9. Europe Market

9.1. Overview
9.2. Market Revenue, by Product Type (2019-2032)
9.3. Market Revenue, by Source (2019-2032)
9.4. Market Revenue, by Service Type (2019-2032)
9.5. Market Revenue, by Therapeutic Area (2019-2032)
9.6. Market Revenue, by Country (2019-2032)

Chapter 10. Asia-Pacific Market

10.1. Overview
10.2. Market Revenue, by Product Type (2019-2032)
10.3. Market Revenue, by Source (2019-2032)
10.4. Market Revenue, by Service Type (2019-2032)
10.5. Market Revenue, by Therapeutic Area (2019-2032)
10.6. Market Revenue, by Country (2019-2032)

Chapter 11. Latin America Market

11.1. Overview
11.2. Market Revenue, by Product Type (2019-2032)
11.3. Market Revenue, by Source (2019-2032)
11.4. Market Revenue, by Service Type (2019-2032)
11.5. Market Revenue, by Therapeutic Area (2019-2032)
11.6. Market Revenue, by Country (2019-2032)

Chapter 12. Middle East and Africa Market

12.1. Overview
12.2. Market Revenue, by Product Type (2019-2032)
12.3. Market Revenue, by Source (2019-2032)
12.4. Market Revenue, by Service Type (2019-2032)
12.5. Market Revenue, by Therapeutic Area (2019-2032)
12.6. Market Revenue, by Country (2019-2032)

Chapter 13. U.S. Market

13.1. Overview
13.2. Economic Indicators
13.3. Demographics and Population Insights
13.4. Growth Drivers
13.5. Challenges and Barriers
13.6. Competitive Strategies
13.7. Emerging Players
13.8. Market Size and Forecast
- 13.8.1. Market Revenue, by Product Type (2019-2032)
- 13.8.2. Market Revenue, by Source (2019-2032)
- 13.8.3. Market Revenue, by Service Type (2019-2032)
- 13.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 14. Canada Market

14.1. Overview
14.2. Economic Indicators
14.3. Demographics and Population Insights
14.4. Growth Drivers
14.5. Challenges and Barriers
14.6. Competitive Strategies
14.7. Emerging Players
14.8. Market Size and Forecast
- 14.8.1. Market Revenue, by Product Type (2019-2032)
- 14.8.2. Market Revenue, by Source (2019-2032)
- 14.8.3. Market Revenue, by Service Type (2019-2032)
- 14.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 15. Germany Market

15.1. Overview
15.2. Economic Indicators
15.3. Demographics and Population Insights
15.4. Growth Drivers
15.5. Challenges and Barriers
15.6. Competitive Strategies
15.7. Emerging Players
15.8. Market Size and Forecast
- 15.8.1. Market Revenue, by Product Type (2019-2032)
- 15.8.2. Market Revenue, by Source (2019-2032)
- 15.8.3. Market Revenue, by Service Type (2019-2032)
- 15.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 16. U.K. Market

16.1. Overview
16.2. Economic Indicators
16.3. Demographics and Population Insights
16.4. Growth Drivers
16.5. Challenges and Barriers
16.6. Competitive Strategies
16.7. Emerging Players
16.8. Market Size and Forecast
- 16.8.1. Market Revenue, by Product Type (2019-2032)
- 16.8.2. Market Revenue, by Source (2019-2032)
- 16.8.3. Market Revenue, by Service Type (2019-2032)
- 16.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 17. France Market

17.1. Overview
17.2. Economic Indicators
17.3. Demographics and Population Insights
17.4. Growth Drivers
17.5. Challenges and Barriers
17.6. Competitive Strategies
17.7. Emerging Players
17.8. Market Size and Forecast
- 17.8.1. Market Revenue, by Product Type (2019-2032)
- 17.8.2. Market Revenue, by Source (2019-2032)
- 17.8.3. Market Revenue, by Service Type (2019-2032)
- 17.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 18. Italy Market

18.1. Overview
18.2. Economic Indicators
18.3. Demographics and Population Insights
18.4. Growth Drivers
18.5. Challenges and Barriers
18.6. Competitive Strategies
18.7. Emerging Players
18.8. Market Size and Forecast
- 18.8.1. Market Revenue, by Product Type (2019-2032)
- 18.8.2. Market Revenue, by Source (2019-2032)
- 18.8.3. Market Revenue, by Service Type (2019-2032)
- 18.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 19. Spain Market

19.1. Overview
19.2. Economic Indicators
19.3. Demographics and Population Insights
19.4. Growth Drivers
19.5. Challenges and Barriers
19.6. Competitive Strategies
19.7. Emerging Players
19.8. Market Size and Forecast
- 19.8.1. Market Revenue, by Product Type (2019-2032)
- 19.8.2. Market Revenue, by Source (2019-2032)
- 19.8.3. Market Revenue, by Service Type (2019-2032)
- 19.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 20. China Market

20.1. Overview
20.2. Economic Indicators
20.3. Demographics and Population Insights
20.4. Growth Drivers
20.5. Challenges and Barriers
20.6. Competitive Strategies
20.7. Emerging Players
20.8. Market Size and Forecast
- 20.8.1. Market Revenue, by Product Type (2019-2032)
- 20.8.2. Market Revenue, by Source (2019-2032)
- 20.8.3. Market Revenue, by Service Type (2019-2032)
- 20.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 21. India Market

21.1. Overview
21.2. Economic Indicators
21.3. Demographics and Population Insights
21.4. Growth Drivers
21.5. Challenges and Barriers
21.6. Competitive Strategies
21.7. Emerging Players
21.8. Market Size and Forecast
- 21.8.1. Market Revenue, by Product Type (2019-2032)
- 21.8.2. Market Revenue, by Source (2019-2032)
- 21.8.3. Market Revenue, by Service Type (2019-2032)
- 21.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 22. Japan Market

22.1. Overview
22.2. Economic Indicators
22.3. Demographics and Population Insights
22.4. Growth Drivers
22.5. Challenges and Barriers
22.6. Competitive Strategies
22.7. Emerging Players
22.8. Market Size and Forecast
- 22.8.1. Market Revenue, by Product Type (2019-2032)
- 22.8.2. Market Revenue, by Source (2019-2032)
- 22.8.3. Market Revenue, by Service Type (2019-2032)
- 22.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 23. South Korea Market

23.1. Overview
23.2. Economic Indicators
23.3. Demographics and Population Insights
23.4. Growth Drivers
23.5. Challenges and Barriers
23.6. Competitive Strategies
23.7. Emerging Players
23.8. Market Size and Forecast
- 23.8.1. Market Revenue, by Product Type (2019-2032)
- 23.8.2. Market Revenue, by Source (2019-2032)
- 23.8.3. Market Revenue, by Service Type (2019-2032)
- 23.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 24. Australia Market

24.1. Overview
24.2. Economic Indicators
24.3. Demographics and Population Insights
24.4. Growth Drivers
24.5. Challenges and Barriers
24.6. Competitive Strategies
24.7. Emerging Players
24.8. Market Size and Forecast
- 24.8.1. Market Revenue, by Product Type (2019-2032)
- 24.8.2. Market Revenue, by Source (2019-2032)
- 24.8.3. Market Revenue, by Service Type (2019-2032)
- 24.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 25. Brazil Market

25.1. Overview
25.2. Economic Indicators
25.3. Demographics and Population Insights
25.4. Growth Drivers
25.5. Challenges and Barriers
25.6. Competitive Strategies
25.7. Emerging Players
25.8. Market Size and Forecast
- 25.8.1. Market Revenue, by Product Type (2019-2032)
- 25.8.2. Market Revenue, by Source (2019-2032)
- 25.8.3. Market Revenue, by Service Type (2019-2032)
- 25.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 26. Mexico Market

26.1. Overview
26.2. Economic Indicators
26.3. Demographics and Population Insights
26.4. Growth Drivers
26.5. Challenges and Barriers
26.6. Competitive Strategies
26.7. Emerging Players
26.8. Market Size and Forecast
- 26.8.1. Market Revenue, by Product Type (2019-2032)
- 26.8.2. Market Revenue, by Source (2019-2032)
- 26.8.3. Market Revenue, by Service Type (2019-2032)
- 26.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 27. Saudi Arabia Market

27.1. Overview
27.2. Economic Indicators
27.3. Demographics and Population Insights
27.4. Growth Drivers
27.5. Challenges and Barriers
27.6. Competitive Strategies
27.7. Emerging Players
27.8. Market Size and Forecast
- 27.8.1. Market Revenue, by Product Type (2019-2032)
- 27.8.2. Market Revenue, by Source (2019-2032)
- 27.8.3. Market Revenue, by Service Type (2019-2032)
- 27.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 28. South Africa Market

28.1. Overview
28.2. Economic Indicators
28.3. Demographics and Population Insights
28.4. Growth Drivers
28.5. Challenges and Barriers
28.6. Competitive Strategies
28.7. Emerging Players
28.8. Market Size and Forecast
- 28.8.1. Market Revenue, by Product Type (2019-2032)
- 28.8.2. Market Revenue, by Source (2019-2032)
- 28.8.3. Market Revenue, by Service Type (2019-2032)
- 28.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 29. U.A.E. Market

29.1. Overview
29.2. Economic Indicators
29.3. Demographics and Population Insights
29.4. Growth Drivers
29.5. Challenges and Barriers
29.6. Competitive Strategies
29.7. Emerging Players
29.8. Market Size and Forecast
- 29.8.1. Market Revenue, by Product Type (2019-2032)
- 29.8.2. Market Revenue, by Source (2019-2032)
- 29.8.3. Market Revenue, by Service Type (2019-2032)
- 29.8.4. Market Revenue, by Therapeutic Area (2019-2032)

Chapter 30. Company Profiles

Chapter 31. Appendix

31.1. Sources and References
31.2. Related Reports

Biosimilar Contract Manufacturing Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2026 - 2032)